There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genfit SA (GNFT) and Innate Pharma (IPHA) with bullish sentiments.
Genfit SA (GNFT)
In a report issued on February 9, Arsene Guekam from Kepler Capital maintained a Buy rating on Genfit SA, with a price target of EUR7.50. The company’s shares closed last Wednesday at $6.06, close to its 52-week low of $3.63.
According to TipRanks.com, Guekam is a 4-star analyst with an average return of 10.1% and a 45.0% success rate. Guekam covers the Healthcare sector, focusing on stocks such as Pharnext SA, Guerbet SA, and Galapagos.
Genfit SA has an analyst consensus of Hold, with a price target consensus of $7.36.
See today’s analyst top recommended stocks >>
Innate Pharma (IPHA)
Kepler Capital analyst Damien Choplain upgraded Innate Pharma to Buy on February 9 and set a price target of EUR5.00. The company’s shares closed last Wednesday at $4.54.
Choplain has an average return of 6.6% when recommending Innate Pharma.
According to TipRanks.com, Choplain is ranked #1898 out of 7296 analysts.
Currently, the analyst consensus on Innate Pharma is a Moderate Buy with an average price target of $6.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
